451 results about "Monovalent Cations" patented technology

Processes for synthesizing borohydride compounds with reduced energy requirements and high efficiency are disclosed. The processes include the reaction of a base with a borane complex or diborane to produce a borohydride compound of formula YBH4, where Y is a monovalent cationic moiety.

The present invention relates to a process for preparing a fluoropolymer containing at least one kind of fluoroolefin, which comprises carrying out polymerization in the presence of a surfactant represented by the formula (1): (wherein R1 and R2 may be the same or different respectively, and represent an alkyl group or an alkenyl group, R3 is a hydrogen atom, an alkyl group or an alkenyl group, the total carbon number of R1 to R3 is 2 to 25, L− is a group represented by —SO3−, —OSO3−, —PO3−, —OPO3− or —COO−, and M+ is a monovalent cation). Thereby, polymerization can be carried out with excellent production efficiency in the presence of a small amount of a surfactant, and a fluoropolymer can be prepared without lowering various physical properties such as water resistance by the surfactant.

There is provided a prodrug of a pharmaceutically active agent, such prodrug comprising a beta-keto carboxylic acid, a beta-keto carboxylic acid salt or a beta-keto carboxylic acid ester functional group, a pharmaceutical composition comprising the prodrug, and to the use of the prodrug or composition for treatment of a mammalian subject suffering from a condition which can be cured or alleviated by administration of the pharmaceutically active agent. There is further provided a method of inhibiting decarboxylation of a compound comprising a beta-keto carboxylic acid or a salt thereof with a monovalent cation, characterized in that a dry salt of the beta-keto carboxylic acid with a divalent or polyvalent cation is prepared.

The present invention relates to a sulfonic acid group-containing polymer excellent in ion conductivity and durability, a method for producing the same, a resin composition containing the sulfonic acid group-containing polymer, a polymer electrolyte membrane, a polymer electrolyte membrane / electrode assembly, and a fuel cell. The sulfonic acid group-containing polymer of the present invention, in a first embodiment, includes a constituent represented by the following chemical formula 1:wherein X represents hydrogen or a monovalent cation species; Y represents a sulfone group or a ketone group; and n represents an arbitrary integer not less than 2.

A compound of an angiotensin receptor antagonist (ARB), a neutral endopeptidase inhibitor (NEPi) and one or more monovalent cations are useful for the treatment of hypertension and / or heart failure. ARB includes S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine in the anion form, NEPi includes (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester in the anion form and cation includes monovalent cations such as Na+. The compound includes trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3′-methyl-2′-(pentanoyl{2″-(tetrazol-5-ylate)biphenyl-4′-ylmethyl}amino)butyrate] hemipentahydrate.

Compositions, kits and methods are provided for restoring skin barrier function to skin exposed to environmental elements and / or in a pathological condition. In general, divalent cations such as calcium ions and / or magnesium ions are included in a physiologically acceptable medium. In some embodiments, divalent cations are balanced with monovalent cations such as sodium and potassium ions at appropriate ratios in order to maintain the homeostasis of skin barrier. The compositions, kits and methods can be used as cosmetics, cosmeceuticals or pharmaceuticals for improving skin condition, and preventing or treating dermatological diseases and skin disorders.

The invention is directed to an electrode which has been coated with the solid ion conductor which has a garnet-like crystal structure and has the stoichiometric composition L7+xAxG3−xZr2O12, whereinL is in each case independently a monovalent cation,A is in each case independently a divalent cation,G is in each case independently a trivalent cation,0≦x≦3 andO can be partly or completely replaced by divalent or trivalent anion.

Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I):Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and / or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.

The present invention is a fluoropolymer comprising a plurality of pendent groups terminating in —CF2SO3X, —CF2SO2F, or combinations thereof, where X is selected from a group consisting of H+ and a monovalent cation, and at least one —CF2Y end group, where Y is selected from a group consisting of a chlorine atom, a bromine atom, an iodine atom, a nitrile group, and an —SO3X group.

A novel semi-batch emulsion polymerization process for the production of fluoroelastomers is disclosed wherein a hydrocarbon anionic surfactant is employed as the dispersing agent. The surfactant has the formula R-L-M wherein R is an alkyl group having between 6 and 17 carbon atoms, L is selected from the group consisting of ArSO3−, SO3−, SO4−, PO3− and COO− and M is a univalent cation. Preferred surfactants are sulfonates of the formula CH3—(CH2)n—SO3M, CH3—(CH2)n—C6H4—SO3M, or CH3—(CH2)n—CH═CHCH2—SO3M, where n is an integer from 6 to 17, or mixtures thereof, and M is a cation having a valence of 1. Surfactant is not introduced to the reactor until shortly after the polymerization reaction has begun.

The present invention is directed to an isomerized alpha olefin sulfonate and a method of making the same wherein the isomerized alpha olefin sulfonate is derived from sulfonating an isomerized alpha olefin with sulfur trioxide in the presence of air thereby producing an isomerized alpha olefin sulfonic acid, wherein the isomerized alpha olefin is derived from the isomerization of C12-C40 normal alpha olefins; and neutralizing the isomerized alpha olefin sulfonic acid with a source of a mono-valent cation.

The present invention is directed to a composition useful for making homogeneously mineralized self assembled peptide-amphiphile nanofibers and nanofiber gels. The composition is generally a solution comprised of a positively or negatively charged peptide-amphiphile and a like signed ion from the mineral. Mixing this solution with a second solution containing a dissolved counter-ion of the mineral and / or a second oppositely charged peptide amphiphile, results in the rapid self assembly of the peptide-amphiphiles into a nanofiber gel and templated mineralization of the ions. Templated mineralization of the initially dissolved mineral cations and anions in the mixture occurs with preferential orientation of the mineral crystals along the fiber surfaces within the nanofiber gel. One advantage of the present invention is that it results in homogenous growth of the mineral throughout the nanofiber gel. Another advantage of the present invention is that the nanofiber gel formation and mineralization reactions occur in a single mixing step and under substantially neutral or physiological pH conditions. These homogeneous nanostructured composite materials are useful for medical applications especially the regeneration of damaged bone in mammals. This invention is directed to the synthesis of peptide-amphiphiles with more than one amphiphilic moment and to supramolecular compositions comprised of such multi-dimensional peptide-amphiphiles. Supramolecular compositions can be formed by self assembly of multi-dimensional peptide-amphiphiles by mixing them with a solution comprising a monovalent cation.

The invention relates to a fluorination process for producing fluorinated compounds.The process consists in reacting a compound (I) corresponding to the formulawith an ionic fluoride of a monovalent cation. M represents H, an alkali metal, a quaternary phosphonium group or a quaternary ammonium group. Y represents SO2 and m is 1, or else Y is PO and m is 2. Z represents CR2, N or P. R1 represents an electron-withdrawing group which has a Hammet σP parameter of greater than 0.4. R2 represents a carbonaceous and / or electron-withdrawing group. X represents a halogen other than a fluorine.The fluorinated compounds obtained are of use in particular as electrolytes in lithium batteries.

Methods of controlling emissions from a diesel engine are provided. The method includes contacting the emissions with a perovskite-type catalyst consisting essentially of a metal oxide composition represented by the general formula Aa-xBxMOb, in which A is a mixture originally in the form of single phase mixed lanthanides collected from bastnasite; B is a divalent or monovalent cation; M is at least one element selected from the group consisting of M is at least one element selected from the group consisting of elements of an atomic number of from 22 to 30, 40 to 51, and 73 to 80; a is 1 or 2; b is 3 when a is 1 or b is 4 when a is 2; and x is a number defined by 0<x<0.7. The perovskite-type catalyst may be used to oxidize hydrocarbons and carbon monoxide and to control particulate emissions in the diesel exhaust.

Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I): Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and / or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.